Toward a Complete Set of Germline Null and Modifiable Mutations in Drosophila
Award amount
$1,547,706Program and phase
SBIR · Phase IIAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- GENETIVISION CORPORATION
- Proposal award date
- 2017-08-15
- Contract end date
- 2019-07-31
- UEI
- DCR3JT98KGB7
- Solicitation number
- PA18-591
- Topic code
- 200
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A Precisely Controllable Loss-of-Function Mutation Collection in Drosophila
- A Conditional Loss-of-Function Mutation Collection in Drosophila
- Toward a Complete Set of Germline Null and Modifiable Mutations in Drosophila
- A New Tool Kit for Whole-Genome Mapping and Complementation in Drosophila
- A New Tool Kit for Whole-Genome Mapping and Complementation in Drosophila
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Electromagnetic reprogramming of systemic metabolism for the treatment of type 2 diabetes
- Next-Gen Oral Therapeutics for Type 2 Diabetes
- Oral Therapeutics Platform for Treating Inborn Errors of Amino Acid Metabolism
- Development of novel therapeutics for obesity and type 2 diabetes
- Metrifonate local application for DFU treatment
Research funding history
6 SBIR/STTR records share this UEI (2012–2025). Reported award amounts total $7,144,442. Reported amounts are not federal obligations.
Phases: Phase II, Phase I, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services